| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | NAC1; BEND8; NAC-1; BTBD14B; FLJ37383; NACC1 |
| Entrez GeneID | 112939 |
| clone | 6H2 |
| WB Predicted band size | 58kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human NACC1 expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于NACC1抗体的3篇文献概述，供参考：
---
1. **文献名称**: "NACC1 as a transcriptional regulator in neuroblastoma pathogenesis"
**作者**: Smith J, et al.
**摘要**: 本研究利用兔源多克隆NACC1抗体，通过Western blot和免疫组化分析了NACC1在神经母细胞瘤组织中的表达。结果显示，NACC1高表达与肿瘤分化程度及患者预后显著相关，抗体特异性通过siRNA敲低实验验证。
---
2. **文献名称**: "Characterization of a monoclonal antibody against human NACC1 for epigenetic studies"
**作者**: Lee H, et al.
**摘要**: 文章报道了一种新型小鼠单克隆NACC1抗体的开发，验证了其在染色质免疫沉淀(ChIP)和免疫荧光中的应用。抗体通过重组人NACC1蛋白免疫制备，成功用于探究NACC1在染色质重塑复合体中的调控作用。
---
3. **文献名称**: "NACC1 overexpression in ovarian cancer: Implications for biomarker discovery"
**作者**: Garcia R, et al.
**摘要**: 研究使用商业化NACC1抗体(Abcam货号AB12345)，结合免疫组化技术，发现NACC1在卵巢癌组织中显著上调，并与化疗耐药性相关。实验通过敲除细胞系验证抗体特异性，支持其作为潜在生物标志物的价值。
---
**备注**：以上文献信息为示例，实际引用需根据具体研究核实准确性。建议通过PubMed或Web of Science以“NACC1 antibody”及“NACC1 protein detection”为关键词检索最新文献。
The NACC1 (Nucleus Accumbens Associated 1) gene encodes a transcriptional regulator implicated in diverse cellular processes, including proliferation, differentiation, and apoptosis. It belongs to the BTB/POZ protein family, characterized by a conserved N-terminal BTB domain that facilitates protein-protein interactions and a C-terminal NPR (NACC1. PRC1. and RYBP) domain involved in chromatin remodeling. NACC1 modulates gene expression by interacting with histone deacetylases (HDACs) and polycomb group proteins, influencing epigenetic regulation.
Dysregulation of NACC1 is linked to multiple pathologies. Germline mutations cause neurodevelopmental disorders such as hypotonia, seizures, and developmental delay, often classified as NACC1-associated autosomal dominant syndrome. Somatic NACC1 aberrations are observed in cancers, including glioblastoma and ovarian carcinoma, where it may act as an oncogene. Additionally, NACC1 overexpression correlates with chemoresistance in some malignancies.
NACC1 antibodies are essential tools for studying its expression, localization, and function. They enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding research into its role in disease mechanisms. Commercial antibodies target specific epitopes or post-translational modifications, supporting both diagnostic and therapeutic investigations. Continued research on NACC1 and its antibodies holds promise for uncovering novel biomarkers and targeted therapies in oncology and neurodevelopmental disorders.
×
